In Tau-expressing wild-type MEFs, six-hour IU1 exposure reduced Tau protein, with no corresponding reduction in Usp14-null MEFs. Proteasome-inhibitor controls antagonized Tau depletion, while the ubiquitin-independent substrate cODC-EGFP showed little or no response. [1]
Primary rat cortical neurons showed reduced MTT signal and ATP following IU1 exposure in concentration/time experiments. Co-treatment with PGJ2 further reduced these endpoints. This neuronal bioenergetic response limits extrapolation of the MEF findings; reduced MTT signal alone does not quantify neuronal loss. [2]
Reversible inhibition of proteasome-associated USP14
Biochemical assay · Recombinant human USP14 associated with Ub-VS-treated human 26S proteasomes; Ub-AMC hydrolysis [1]
IU1 inhibited proteasome-associated USP14. The tested DUB panel and recovery after compound removal support selectivity within that panel and reversible inhibition.
Literature-Reported Treatment Conditions
- Treatment concentration
- Dose-response assay: 50 nM–100 μM IU1 for USP14; selectivity panel: 17 μM; reversibility: 100 μM
- Exposure duration
- IC50: 30 min preincubation followed by 45 min monitoring; reversibility exposure: 2 h
- Method
- Cell-free enzyme activity assays and compound-removal control
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: IU1; Compound label in the paper: IU1
Evidence applies to the reported experimental IU1 material and model; it does not validate an Adooq lot.
Fig. 2a–d and caption; full Methods: DUB activity assay, IC50 value determination, IU1 reversibility test
Inhibition of proteasome-associated USP14 Ub-AMC hydrolysis: Mean ± s.d.; n=3. Enzyme/compound preincubation 30 min, 1 μM Ub-AMC; fluorescence monitored at room temperature for 45 min. — Fig. 2b caption; Methods: IC50 value determination
IsoT and UCH37 inhibition; broader DUB panel: Mean ± s.d.; n=3 in Fig. 2 caption. At 17 μM IU1, Fig. 2c compares USP14 with eight other DUBs; panel selectivity is not a proteome-wide selectivity claim. — Fig. 2b–c and caption; Methods: DUB activity assay
USP14 activity after removal of IU1: 60 nM USP14 and 5 nM human proteasome exposed to 100 μM IU1 or DMSO for 2 h; Ub-AMC activity assayed before/after filtration; mean ± s.d., n=3. No percentage inferred from bars. — Fig. 2d and caption; Methods: IU1 reversibility test
Tau response depends on USP14 and proteasome function in MEFs
Cell-based study · Wild-type and Usp14-null mouse embryonic fibroblasts transiently expressing Tau [1]
IU1 reduced Tau immunoblot signal in wild-type MEFs but not Usp14-null MEFs. Proteasome inhibitors antagonized the response, while the ubiquitin-independent substrate cODC-EGFP showed little or no response.
Literature-Reported Treatment Conditions
- Treatment concentration
- Wild type: 0, 25, 50, 75, 100 μM; Usp14-null: 0, 10, 50, 100 μM; proteasome-control experiment: 50 μM
- Exposure duration
- 6 h
- Method
- Cell treatment followed by immunoblotting
- Vehicle
- Vehicle composition for the Fig. 4a–c cell experiment is not specified in the inspected caption/mammalian-culture subsection.
- Co-treatment
- Control experiment includes MG132 (30 μM) and PS-341 (10 μM); these are mechanistic controls, not an IU1 combination-efficacy claim.
- Reported limits
- Biological replicate count for these representative blots not stated in the inspected caption.
Methods and source locations
Compound reported in the paper: IU1; Compound label in the paper: IU1
Evidence applies to the reported experimental IU1 material and model; it does not validate an Adooq lot.
Fig. 4a–c and caption; Results: A Usp14 inhibitor accelerates proteolysis in cells; Methods: Mammalian cell cultures and transient expression
Tau protein abundance with IU1 in wild-type versus Usp14-null MEFs: Six-hour exposure 36 h after cotransfection; LacZ transfection and actin loading controls. No fold-change or n inferred from representative blots. — Fig. 4a–b and caption
Proteasome dependence and substrate specificity of the Tau response: Wild-type MEFs coexpressing Tau/cODC-EGFP; 50 μM IU1 for 6 h; MG132 30 μM and PS-341 10 μM as proteasome-inhibitor controls. — Fig. 4c and caption; accompanying Results paragraph
IU1 reduces neuronal MTT signal and ATP under matched exposures
Cell-based study · Primary E18 Sprague Dawley rat cerebral cortical neurons (both sexes), experiments at 8–11 days in vitro [2]
Concentration/time experiments found reduced MTT signal and ATP after IU1 exposure. Separate combination comparisons with PGJ2 further reduced both endpoints. MTT is an assay of metabolic reduction and does not establish a direct neuron count.
Literature-Reported Treatment Conditions
- Treatment concentration
- 24 h MTT series (Fig. 3A): 0, 5, 10, 25, 50 μM IU1; 24 h ATP series (Fig. 4A): 0, 5, 10, 25, 50, 75 μM IU1; time series: 25 μM; combination comparison: 25 μM IU1 with 10 μM PGJ2
- Exposure duration
- Concentration/comparison experiments: 24 h; time course: 4, 8, 16, 24 h
- Method
- Cell exposure; MTT and protein-normalized ATP assays
- Vehicle
- 0.5% DMSO
- Co-treatment
- Separate IU1-alone, PGJ2-alone and IU1+PGJ2 groups; combination outcomes are attributed separately.
- Reported limits
- Exact response percentages are not reported here; substantial between-panel variability and ambiguous textual percent-loss wording preclude a single pooled estimate.
Methods and source locations
Compound reported in the paper: IU1; Compound label in the paper: IU1
Evidence applies to the reported experimental IU1 material and model; it does not validate an Adooq lot.
Results 3.2; Figs. 3–4 and captions; Methods 2.1, 2.3–2.6, 2.16
Neuronal MTT reduction relative to DMSO control: Fig. 3 caption describes means and s.e. from at least three independent experiments/group; Results separately gives n=12 for 5 μM. Replicate hierarchy of that n is not clarified. One-way ANOVA with Tukey multiple comparisons in Methods. — Results 3.2; Fig. 3A–C and caption; Methods 2.5, 2.16
Steady-state ATP normalized to protein: Luciferin/luciferase assay; ATP in pmoles/μg protein; means and s.e., at least three independent experiments/group. Exact percentages not extracted: Results describes loss values inconsistently with its “of control” wording. — Fig. 4A–C and caption; Results 3.2; Methods 2.6
Direct mitochondrial Complex I inhibition
Biochemical assay · Permeabilized rat brain mitochondrial membranes [2]
IU1 inhibited NADH-oxidase and NADH:Q1 reductase activities of Complex I. The figure also shows weaker effects on other respiratory activities at higher concentrations, limiting a blanket claim of USP14-only pharmacology.
Literature-Reported Treatment Conditions
- Treatment concentration
- Fig. 5A–B concentration-response curves through 300 μM; Fig. 5C–E: 0, 120, 300 μM
- Exposure duration
- 2 min preincubation before substrate addition
- Method
- Cell-free respiratory-chain activity measurements at 30°C
- Vehicle
- Vehicle for this mitochondrial assay is not explicitly identified in the Fig. 5 caption or Methods 2.7.
Methods and source locations
Compound reported in the paper: IU1; Compound label in the paper: IU1
Evidence applies to the reported experimental IU1 material and model; it does not validate an Adooq lot.
Results 3.3; Fig. 5A–E and caption; Methods 2.1, 2.7, 2.16
NADH:Q1 reductase activity: Approximate value explicitly stated in Results; not fitted from the viewed curve. Spectrophotometry at 30°C after 2 min IU1 preincubation; mean ± S.D., at least 3 independent experiments. — Results 3.3; Fig. 5B and caption
Other mitochondrial respiratory activities at higher IU1 concentrations: 120 and 300 μM IU1 compared with 0 μM. Fig. 5D marks 120 μM ns and 300 μM ***, while Fig. 5E marks increases at 120 μM ** and 300 μM ***. Caption: **p<0.01; ***p<0.001; mean ± S.D., at least 3 independent experiments. No exact magnitudes inferred. — Fig. 5C–E and caption; Results 3.3